证券代码：301206 证券简称：三元生物 公告编号：2025-087 山东三元生物科技股份有限公司 2025 年第五次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东会未出现否决议案的情形。 2、本次股东会未涉及变更以往股东会已通过的决议。 一、会议召开和出席情况 （一）会议召开情况 1、会议召开时间： 现场会议时间：2025 年 11 月 12 日（星期三）15:00 网络投票时间：通过深圳证券交易所交易系统进行网络投票的具体时间为： 2025 年 11 月 12 日 9:15—9:25，9:30—11:30 和 13:00—15:00；通过深圳证券交易 所互联网投票系统的具体时间为：2025 年 11 月 12 日 9:15 至 15:00 2、会议召开地点：山东省滨州市滨北梧桐十路 101 号三元生物公司会议室 3、会议召开方式：现场投票和网络投票相结合的方式 通过现场和网络投票的中小股东 140 人，代表股份 1,230,709 股，占公司有 表决权股份总数的 0.6154%。 4、会议召集人：董事会 5、 ...

Core Viewpoint - San Yuan Bio provided information regarding the specifics of "construction in progress" and its monetary changes, directing investors to refer to the company's "2025 Semi-Annual Report" for detailed financial statements and notes [2] Group 1 - The company addressed investor inquiries on its interactive platform regarding the composition and monetary changes of "construction in progress" [2] - Investors are advised to consult the "Section 8 Financial Report" and "Note 12: Construction in Progress" in the company's upcoming semi-annual report for detailed information [2]

证券代码：301206 证券简称：三元生物 公告编号：2025-086 山东三元生物科技股份有限公司 公司于近日收到股东鲁信资本出具的《关于股份减持计划期满暨实施结果的 告知函》，截至本公告日，上述减持计划已期限届满，现将有关情况公告如下： 一、股东股份减持计划实施情况 | 股东 名称 | 减持方式 | | 减持期间 | | | 减持均价 （元/股） | 减持股数 （股） | 减持比例 （%） | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 大宗交易 | 2025 -2025 | 年 8 年 10 | 月 月 | 7 日 日 29 | 29.35 | 4,000,000 | 2.000% | | 鲁信 资本 | 集中竞价 | 2025 | 年 8 | 月 | 7 日 | 29.27 | 1,990,050 | | | | | -2025 | 年 10 | 月 | 日 29 | | | 0.995% | | | 合计 | | - | | | - | 5,990,050 | 2.995% | （一）股东减持股份情况 1 / 3 注 1、上 ...

Core Viewpoint - The announcement from San Yuan Bio indicates that shareholder Luxin Capital has completed its share reduction plan, which involved a total reduction of approximately 599,005 shares, representing about 2.995% of the total share capital [1] Summary by Sections Shareholder Reduction Plan - Luxin Capital originally planned to reduce its holdings by up to 6 million shares, or 3% of the total share capital, starting from a specific date in 2025 [1] - As of the announcement date, Luxin Capital executed the reduction between August 7 and October 29, 2025, through block trades and centralized bidding [1] Reduction Details - The total shares reduced included 400,000 shares through block trades and 199,005 shares through centralized bidding, culminating in a total of 599,005 shares [1] - Following the reduction, Luxin Capital's holdings decreased to 193,000 shares, which is 0.97% of the total share capital [1] Impact on Company - The share reduction did not result in a change of control for the company and is not expected to have a significant impact on its operations [1]

Core Viewpoint - San Yuan Bio is a leading enterprise in the global erythritol industry, established in 2007 and listed on the Shenzhen Stock Exchange in 2022, with a focus on the research, production, and sales of erythritol and its compound products [1] Financial Performance - In Q3 2025, San Yuan Bio reported revenue of 476 million yuan, ranking 19th among 24 companies in the industry, while the top company, Meihua Biological, achieved revenue of 18.215 billion yuan [2] - The net profit for the same period was 67.2847 million yuan, also ranking 19th, with the industry leader, Xinhecheng, reporting a net profit of 5.354 billion yuan [2] Financial Ratios - As of Q3 2025, San Yuan Bio's debt-to-asset ratio was 3.73%, significantly lower than the industry average of 28.46%, down from 5.03% year-on-year [3] - The gross profit margin for the same period was 16.15%, an increase from 10.30% year-on-year, but still below the industry average of 28.77% [3] Executive Compensation - The chairman, Nie Zaijian, received a salary of 800,000 yuan in 2024, an increase of 77,200 yuan from the previous year [4] - The general manager, Cheng Baohua, saw his salary rise to 765,000 yuan, up by 102,600 yuan from 2023 [4] Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 3.67% to 15,800, while the average number of circulating A-shares held per account increased by 3.81% to 8,248.95 [5]

Group 1: Industry Overview - The Chinese sugar substitute industry has a competitive hierarchy, with companies having registered capital exceeding 500 million yuan, such as Rhein Biotech, Jinhui Industrial, and Morning Light Biological, while those with capital between 200 million to 500 million yuan include Baolingbao and Bailong Chuangyuan [1] - The primary production regions for sugar substitute companies in China are Shandong, Hebei, and Anhui provinces, with Shandong housing the most companies, including Sanyuan Biological, Baolingbao, and Bailong Chuangyuan [1] Group 2: Revenue Rankings - In 2024, Huakang Co., Ltd. leads the revenue ranking among listed sugar substitute companies in China, with sales exceeding 1.9 billion yuan. Baolingbao, Rhein Biotech, and Sanyuan Biological follow, each with revenues exceeding 500 million yuan [5] Group 3: Industry Concentration - The concentration levels in the sugar substitute industry are high for products like sucralose, aspartame, and sugar alcohols. Major manufacturers of sucralose include Jinhui Industrial and Shandong Kangbao, while aspartame is primarily produced by companies like Hanguang Sweeteners and the Vito Company [8] Group 4: Company Layout - Companies like Sanyuan Biological and Huakang Co., Ltd. have a high proportion of their business in sugar substitutes. Many companies focus on sugar alcohol products, with Huakang Co., Ltd. producing over 170,000 tons of crystalline sugar alcohol [9][11] - Key sales markets for Chinese sugar substitute companies include China, the Americas, Europe, and Japan and South Korea [9] Group 5: Competitive Analysis - The competitive state of the sugar substitute industry in China shows moderate competition among existing firms, with a significant threat from potential new entrants due to growing health demands [12] - The bargaining power of upstream suppliers is strong, as the main raw materials are sourced from starch and chemical raw material companies, which are generally larger than the sugar substitute manufacturers [12] - The bargaining power of downstream customers is relatively weak, especially for small clients, while industry leaders maintain some pricing power [12]

Computing - Chuangwei Data reports strong market demand for cloud computing services, with high server rental rates [1] Semiconductor - Tengjing Technology indicates a robust order backlog in the semiconductor equipment sector [1] - Zhongdian Port states that the revenue contribution from the agency of Nexperia semiconductor product line is relatively small [1] - Tianzhun Technology mentions that Suzhou Xihang Semiconductor's inline inspection equipment can be used for quality control in memory chip manufacturing [1] - Glinda has begun mass production of photoresist for semiconductors, supplying leading companies [1] Quantum Technology - Tefa Information currently has no involvement in the quantum technology sector [1] Robotics - Hengfeng Tools has provided tool trial services to over ten humanoid robot component manufacturers [1] Solid-State Batteries - Funeng Technology is steadily constructing its pilot line for solid-state batteries [1] Commercial Aerospace - Zhongji Renjian has not yet initiated any commercial aerospace business [1] Other - Shenling Environment's products are serving a compact fusion energy experimental device project [1] - Shanda Electric Power currently has no business related to controllable nuclear fusion [1] - Sanyuan Bio's intelligent biomass energy project has been terminated due to approval delays [1]

Core Viewpoint - San Yuan Bio (301206) has decided to terminate its planned investment in an intelligent biomass energy project due to approval obstacles [1] Company Summary - The company had initially intended to invest in a smart biomass energy project [1] - The decision to halt the project was made recently following difficulties in obtaining necessary approvals [1]

证券代码：301206 证券简称：三元生物 公告编号：2025-085 山东三元生物科技股份有限公司 关于使用暂时闲置超募资金进行现金管理的进展公告 近日，公司使用暂时闲置超募资金在授权范围内购买了理财产品，现将具体 情况公告如下： | 序 | | | 产品 | | | 认购金额 | 实际年化 | 收益金额 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 号 | 发行主体 | 产品名称 | 类型 | 起始日期 | 到期日期 | （万元） | 收益率 | （万元） | | | | 2025 年挂钩 | | | | | | | | | 中国光大 | 汇率对公结 | | | | | | | | | 银行股份 | | 保本浮 | | | | | | | 1 | | 构性存款定 | | 2025/09/24 | 2025/10/24 | 2,300.00 | 1.65% | 3.16 | | | 有限公司 | | 动收益 | | | | | | | | | 期第九期产 | | | | | | | | | 滨州分行 | | | | | | | | | ...

Group 1 - The core viewpoint of the article highlights that San Yuan Bio (301206.SZ) reported its Q3 2025 financial results, showing a revenue increase but a significant decline in net profit [1] Group 2 - In Q3, the company achieved an operating income of 158 million yuan, representing a year-on-year growth of 14.51% [1] - The net profit for Q3 was 9.92 million yuan, which reflects a year-on-year decrease of 65.91% [1] - For the first three quarters, the company reported a total operating income of 476 million yuan, down 7.54% year-on-year [1] - The net profit for the first three quarters was 81.01 million yuan, showing a year-on-year decline of 16.80% [1]